Author

A. El-Khoueiry

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial.

BACKGROUND & AIMS First-line nivolumab demonstrated a higher objective response rate (ORR) and favorable safety profile vs. sorafenib in advanced HCC in the phase 3 CheckMate 459 trial; however, no significant improvement in overall survival (OS) was observed. Here, we report exploratory biomarker analyses from CheckMa...

J. Neely, Jin Yao, M. Kudo et al. · JHEP Reports · 0 citations

Open access Aug 2026

Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study.

PURPOSE MEDI1191 is a lipid nanoparticle-formulated mRNA designed to induce local interleukin-12 production and intensify antitumor T cell responses. We report dose-escalation results from a first-in-human, open-label, phase I study of intratumoral MEDI1191 plus intravenous durvalumab (NCT03946800). METHODS Patients...

B. Carneiro, Thomas U. Marron, Dmitriy Zamarin et al. · Clinical Cancer Research · 0 citations